CAS 1949-20-8|Oxolamine (citrate)

CHEMICAL IDENTIFICATION

RTECS NUMBER :

RO0720000

CHEMICAL NAME :

1,2,4-Oxadiazole, 5-(2-(diethylamino)ethyl)-3-phenyl-, citrate

CAS REGISTRY NUMBER :

1949-20-8

LAST UPDATED :

199712

DATA ITEMS CITED :

8

MOLECULAR FORMULA :

C14-H19-N3-O.C6-H8-O7

MOLECULAR WEIGHT :

437.50

WISWESSER LINE NOTATION :

T5NO DNJ C2N2&2 ER &QV1XQVQ1VQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

1650 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 16,209,1961

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

351 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

FMXXAJ French Medicament Patent Document. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Discontinued. Volume(issue)/page/year: #683M

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

650 mg/kg

TOXIC EFFECTS :

Kidney, Ureter, Bladder - inflammation, necrosis, or scarring of bladder

REFERENCE :

THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 19,631,1964

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

351 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 16,209,1961 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

43400 mg/kg/7W-I

TOXIC EFFECTS :

Liver - changes in liver weight Kidney, Ureter, Bladder - changes in kidney weight Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :

EMPSAL Experimental and Molecular Pathology, Supplement. (New York, NY) No.1-3, 1963-66. Discontinued. Volume(issue)/page/year: 2,1,1963

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Mammal - dog

DOSE/DURATION :

7177 mg/kg/7W-I

TOXIC EFFECTS :

Gastrointestinal - changes in structure or function of salivary glands Kidney, Ureter, Bladder - inflammation, necrosis, or scarring of bladder Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :

EMPSAL Experimental and Molecular Pathology, Supplement. (New York, NY) No.1-3, 1963-66. Discontinued. Volume(issue)/page/year: 2,1,1963 ** TUMORIGENIC DATA **

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

15 gm/kg/1Y-I

TOXIC EFFECTS :

Tumorigenic - Carcinogenic by RTECS criteria Kidney, Ureter, Bladder - Kidney tumors

REFERENCE :

EMPSAL Experimental and Molecular Pathology, Supplement. (New York, NY) No.1-3, 1963-66. Discontinued. Volume(issue)/page/year: 2,1,1963 ** REPRODUCTIVE DATA **

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Subcutaneous

DOSE :

120 mg/kg

SEX/DURATION :

female 9-11 day(s) after conception

TOXIC EFFECTS :

Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :

ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 17,781,1967

Clin. Ter. 100(5) , 485-92, (1982)

Med. J. Aust. 150(8) , 449-50, 452, (1989)

Twenty reports in Australia, Belgium and The Netherlands have implicated oxolamine-citrate cough-mixtures as a cause of hallucinations in children of less than 10 years of age. Fever is not thought to...

J. Microencapsul. 9(2) , 167-72, (1992)

One of the principal uses of microencapsulation for pharmaceuticals has been the preparation of sustained-release dosage forms which have been usually presented in the form of a suspension or gel. How...